Compare Natco Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA PIRAMAL ENTERPRISES NATCO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 15.4 13.5 113.7% View Chart
P/BV x 3.0 0.9 351.4% View Chart
Dividend Yield % 1.5 2.1 71.5%  

Financials

 NATCO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
PIRAMAL ENTERPRISES
Mar-19
NATCO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,0803,303 32.7%   
Low Rs6711,797 37.4%   
Sales per share (Unadj.) Rs592.1716.5 82.6%  
Earnings per share (Unadj.) Rs188.479.7 236.4%  
Cash flow per share (Unadj.) Rs206.3107.9 191.2%  
Dividends per share (Unadj.) Rs8.2528.00 29.5%  
Dividend yield (eoy) %0.91.1 85.8%  
Book value per share (Unadj.) Rs833.61,477.5 56.4%  
Shares outstanding (eoy) m36.90184.45 20.0%   
Bonus/Rights/Conversions ISIS-  
Price / Sales ratio x1.53.6 41.6%   
Avg P/E ratio x4.632.0 14.5%  
P/CF ratio (eoy) x4.223.6 18.0%  
Price / Book Value ratio x1.11.7 60.9%  
Dividend payout %4.435.1 12.5%   
Avg Mkt Cap Rs m32,311470,292 6.9%   
No. of employees `0004.87.8 61.8%   
Total wages/salary Rs m3,25622,504 14.5%   
Avg. sales/employee Rs Th4,522.516,899.4 26.8%   
Avg. wages/employee Rs Th674.02,877.7 23.4%   
Avg. net profit/employee Rs Th1,439.01,879.9 76.5%   
INCOME DATA
Net Sales Rs m21,848132,153 16.5%  
Other income Rs m4043,128 12.9%   
Total revenues Rs m22,252135,281 16.4%   
Gross profit Rs m9,28466,290 14.0%  
Depreciation Rs m6625,202 12.7%   
Interest Rs m15444,097 0.3%   
Profit before tax Rs m8,87220,119 44.1%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9208,611 22.3%   
Profit after tax Rs m6,95214,701 47.3%  
Gross profit margin %42.550.2 84.7%  
Effective tax rate %21.642.8 50.6%   
Net profit margin %31.811.1 286.0%  
BALANCE SHEET DATA
Current assets Rs m21,307122,742 17.4%   
Current liabilities Rs m5,920310,810 1.9%   
Net working cap to sales %70.4-142.3 -49.5%  
Current ratio x3.60.4 911.4%  
Inventory Days Days7323 317.5%  
Debtors Days Days10739 274.2%  
Net fixed assets Rs m14,986116,904 12.8%   
Share capital Rs m369369 100.0%   
"Free" reserves Rs m30,353272,161 11.2%   
Net worth Rs m30,760272,530 11.3%   
Long term debt Rs m0270,196 0.0%   
Total assets Rs m37,151856,261 4.3%  
Interest coverage x58.61.5 4,024.8%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.60.2 381.0%   
Return on assets %19.16.9 278.5%  
Return on equity %22.65.4 419.0%  
Return on capital %29.312.4 236.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32215,200 67.9%   
Fx outflow Rs m2,9784,889 60.9%   
Net fx Rs m7,34310,312 71.2%   
CASH FLOW
From Operations Rs m4,636-115,975 -4.0%  
From Investments Rs m-11,155-8,265 135.0%  
From Financial Activity Rs m6,509107,525 6.1%  
Net Cashflow Rs m-18-16,650 0.1%  

Share Holding

Indian Promoters % 52.0 52.9 98.4%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 4.0 196.0%  
FIIs % 16.6 26.6 62.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 16.5 157.6%  
Shareholders   25,395 93,274 27.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  DR. REDDYS LAB  NOVARTIS  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

What Should You Do in Today's Volatile Markets?(Podcast)

The week gone by was pretty volatile for Dalal street and the global environment is as unpredictable as it can get.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Small Cap Stocks Could Triple in Less than 2 Years... Here's Why(Profit Hunter)

Sep 30, 2019

Historical data backs up my conviction.

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Sep 30, 2019

Select dividend stocks can be very rewarding.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Oct 11, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS